Response Biomedical Receives Approval to Market NT-proBNP Congestive Heart Failure Marker Test in Canada

    VANCOUVER, June 12 /CNW/ - Response Biomedical Corporation (TSX-V: RBM,
OTCBB: RPBIF) today announced that it has been granted a medical device
license by Health Canada to market its RAMP(R) NT-proBNP Test. Measurement of
NT-proBNP aids in the diagnosis and assessment of severity in individuals
suspected of having congestive heart failure (CHF) and may aid in the risk
stratification of patients with acute coronary syndrome and heart failure.
This allows the Company to market, in Canada, diagnostic tests for a full line
of cardiac markers for acute myocardial infarction (AMI) and congestive heart
failure (CHF). The Company currently markets the product in Europe and has
applied for FDA clearance of the test in the United States.
    "We are very pleased to receive country of origin approval to market the
NT-proBNP test in Canada," said Bill Radvak, President and CEO. "We have been
able to offer a comprehensive line of AMI diagnostics, including Troponin I,
CK-MB and Myoglobin, and the addition of NT-proBNP for CHF should heighten
interest in our cardiovascular product line."

    About CHF

    CHF impedes the ability of the heart to pump blood at a rate sufficient
to support the body's vital needs. CHF affects nearly 17 million people
worldwide, and is the single most frequent cause of hospitalization in people
over 65 years. The initial diagnosis of CHF is problematic as symptoms can be
associated with other pathologies such as respiratory disease and the
secondary effects of obesity. According to the Canadian Heart and Stoke
Foundation, doctors estimate that there are 200,000-300,000 Canadians with
heart failure. Since 1970, the number of Canadians dying from congestive heart
failure has increased sixty per cent. According to the American Heart
Association, approximately five million Americans are currently afflicted with
CHF and 550,000 new cases are diagnosed each year. The prevalence of CHF is
expected to continue increasing due to the aging population and improved
survival rates of patients with other cardiovascular diseases.

    About NT-proBNP

    NT-proBNP is widely recognized as a definitive marker for the diagnosis
of CHF. NT-proBNP is cleaved from the precursor peptide proBNP in quantities
directly proportional to its biologically active counterpart BNP and in close
correlation with the severity of heart failure. BNP is secreted primarily from
the left ventricle in response to pressure overload and regulates blood
pressure, electrolyte balance and fluid volume. BNP acts to reduce the
pressure overload. Elevated levels of NT-proBNP indicate the presence of heart
failure, and provide physicians with an important diagnostic tool in the early
detection and management of CHF. Independent published studies show that
NT-proBNP is also valuable for: risk stratification of patients with stable
coronary heart disease, as a prognostic marker across the entire spectrum of
cardiovascular diseases, potentially detecting early stages of CHF in the
absence of clinically obvious symptoms, and for the assessment of prognosis
for patients with CHF and for patients who have previously had a myocardial
infarction (references available upon request).

    About Response Biomedical

    Response Biomedical develops, manufactures and markets rapid on-site
diagnostic tests for use with its portable RAMP Platform for clinical and
environmental applications. RAMP represents a new paradigm in diagnostics that
provides high sensitivity and reliable information in minutes. It is ideally
suited to both point-of-care testing and laboratory use. The RAMP system
consists of a portable fluorescent reader and single-use disposable test
cartridges, and has the potential to be adapted to more than 250 medical and
non-medical tests currently performed in laboratories. RAMP clinical tests are
commercially available for the early detection of heart attack and congestive
heart failure.
    In late 2006, the Company announced a strategic alliance with 3M Company
to commercialize rapid infectious disease tests.
    In the non-clinical market, RAMP Tests are currently provided for the
environmental detection of West Nile Virus, and biodefense applications
including the rapid on-site detection of anthrax, smallpox, ricin and
botulinum toxin. Several other product applications are under development. The
Company has achieved CE Marking and its Quality Management System is
registered to ISO 13485: 2003 and ISO 9001: 2000.
    Response Biomedical is a publicly traded company, listed on the TSX 
Venture Exchange under the trading symbol "RBM" and quoted on the OTC Bulletin
Board under the symbol "RPBIF". For further information, please visit the
Company's website at

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this release.

    Statements contained in this press release relating to future results,
events or developments, for example, statements containing the words
"believes," "may," "could", "plans," "will," "estimate," "continue,"
"anticipates," "intends," "expects", "goal" and similar expressions, are
"forward-looking statements" or "forward-looking information" under applicable
United States and Canadian securities laws. Forward-looking statements or
information may involve, but are not limited to, comments with respect to our
planned activities, business plan and strategies and their future
implementation, and our expectations for our financial condition and the
results of, or outlook for, our business operations generally. Forward-looking
statements or information are subject to the related assumptions made by us
and involve known and unknown risks, uncertainties and other factors that may
cause actual results, events or developments to be materially different from
those expressed or implied by such statements or information.
    Many of such risks, uncertainties and other factors form part of our
underlying assumptions, and include, among other things, our need for
substantial additional funding to conduct research and development and
commercialization activities; our ability to establish, and our dependence
upon, relationships with strategic alliance partners to develop and
commercialize products; technological changes that impact our existing
products or our ability to develop and commercialize our products; our ability
to obtain and enforce timely patent and other intellectual property protection
for our technology and products; our ability to obtain and maintain rights to
technology from licensors; commercialization limitations imposed by patents
owned or controlled by third parties; our ability to retain, and our reliance
upon, third party suppliers, manufacturers and distributors; our ability to
attract and retain qualified personnel; our ability to effectively and
efficiently manage the planned growth of our operations; our ability to
obtain, and the timing of, necessary regulatory approvals; our ability to
profitably sell our products at prices that would be acceptable to third-party
reimbursement programs; market acceptance of our products and the size of our
markets; changes in business strategy or development plans; changes in, or the
failure to comply with, governmental regulations; and other factors referenced
in our annual report on Form 20-F and other filings with Canadian and United
States securities regulatory authorities.
    Given these uncertainties, assumptions and risks, readers are cautioned
not to place undue reliance on such forward-looking statements or information.
We disclaim any obligation to update, or to publicly announce any revisions
to, any such statements or information to reflect future results, events or

For further information:

For further information: Response Biomedical Contacts: Bill Wickson,
Manager, Investor Relations, Response Biomedical Corporation, Tel (604)
456-6073, Email:; Brian Korb, Vice President, The
Trout Group LLC, Tel: (646) 378-2923, Email:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890